Seven Fleet Capital Management LP lowered its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 58.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,774 shares of the company’s stock after selling 2,542 shares during the quarter. Seven Fleet Capital Management LP’s holdings in Krystal Biotech were worth $659,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Silvant Capital Management LLC purchased a new stake in shares of Krystal Biotech in the second quarter worth $30,000. Western Wealth Management LLC purchased a new position in shares of Krystal Biotech during the 1st quarter valued at $34,000. Greenline Wealth Management LLC purchased a new stake in Krystal Biotech in the 4th quarter worth $34,000. Danske Bank A S bought a new stake in Krystal Biotech during the third quarter valued at about $35,000. Finally, UMB Bank n.a. raised its holdings in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares during the period. 86.29% of the stock is currently owned by institutional investors.
Insider Transactions at Krystal Biotech
In related news, EVP John Thomas sold 1,000 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the sale, the insider directly owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,000 shares of company stock valued at $17,558,270 in the last ninety days. Corporate insiders own 13.10% of the company’s stock.
Krystal Biotech Trading Down 3.6%
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The business had revenue of $119.22 million during the quarter, compared to analysts’ expectations of $120.93 million. On average, research analysts forecast that Krystal Biotech, Inc. will post 7.48 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on KRYS shares. Bank of America upped their price objective on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Wall Street Zen lowered shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings cut shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. HC Wainwright boosted their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a report on Tuesday, June 16th. Finally, Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Krystal Biotech has an average rating of “Moderate Buy” and an average target price of $365.40.
View Our Latest Stock Analysis on KRYS
Krystal Biotech Company Profile
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Articles
- Five stocks we like better than Krystal Biotech
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
